a third author. Data were extracted for the categories of study identification, level of study design, sample size, any runin before the trial, dosage of the active drug, and duration of the study.
Methods of synthesis
How were the studies combined? Pooled odds ratios (ORs) and mean differences were calculated with 95% confidence intervals (CIs).
How were differences between studies investigated?
The authors state that they tested for heterogeneity and if positive, pooling was not performed. However the data for these tests are not given.
Results of the review
Fifty-four studies were included in the review. Forty-four studies (7,590 participants, 2 studies (247 participants) did not specify how participants were assigned to groups) assessed the efficacy of an active drug in comparison with placebo or no treatment (4,273 in the intervention groups and 3,564 in the control groups). Three of the 44 studies as well as ten further studies compared two active drugs (7,201 participants (3,562 active/3,639 control).
Active treatment versus controls studies:
Total walking distance was assessed with aspirin, ticlopidine, suloctidil, indobufen, and defibrotide, and results were similar to those observed for pain-free walking distance, but did not reach statistical significance, except for indobufen and defibrotide, which increased total walking distance for a (common) difference of the means of 98.3 m (95% CI: 49.2, 147), and to 88.8 m (95% CI: 45, 132.6), respectively. Lower-limb arterial occlusions were statistically significantly decreased by aspirin (OR 0.46, 95% CI: 0.27, 0.77) and the number of revascularisation procedures performed were statistically significantly decreased by ticlopidine (OR 0.62, 95% CI: 0.41, 0.93). At least one haemodynamic measure (ankle brachial index or calf blood flow, at rest or after exercise) was assessed with all drugs. In general, no differences in favour of actively treated patients were detected compared to control, except for patients receiving aspirin (after exercise calf blood flow: common difference of the means, in ml/100 ml/min, 2.6, 95% CI: 0.28, 4.91), vitamin K inhibitors (ankle brachial index at rest or after exercise: difference of the means 0.1, 95% CI: 0.01, 0.19, and 0.09, 95% CI: 0.02, 0.2, respectively), defibrotide (ankle brachial index at rest: difference of the means 0.04, 95% CI: 0.01, 0.07; calf blood flow at rest: difference of the means 1.1 ml/100 ml/units, 95% CI: 0.76, 1.4).
A small but statistically significant improvement in pain-free walking distance was determined by picotamide, indobufen, low molecular weight heparins, sulodexide and defibrotide, in small studies.
Comparative studies:
Main comparisons regarded ticlopidine, aspirin, clopidogrel (13 studies). Clopidogrel compared to aspirin (1 study) reported superiority for clopidogrel in rate of vascular events (any vascular death, stroke, myocardial infarction) with OR 0.76, 95% CI: 0.63, 0.92; p = 0.004). The OR for vascular death at the end of treatment period was 0.77, 95% CI: 0.58, 1.03; p = 0.075, which was not statistically significant.
With regard to the results observed with indobufen on walking distance, the heterogeneity test was positive and results were not pooled.
